New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023
7 affiliations
- 1Universidad Santiago de Cali
- 2Clinica de Occidente
- 3University of Caldas
- 4Ministerio de Salud Publica de Ecuador
- 5EpiHealth Research Center for Epidemiology and Public Health
- 6Vicerrectorado de Investigación, Universidad Señor de Sipán
- 7Oficina de Inteligencia Sanitaria, Red Prestacional Lambayeque
Abstract
Background: New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI).
Methods: This retrospective cohort included 218 patients without documented pre-existing atrial fibrillation who underwent TAVI in Cali, Colombia, between 2009 and 2023. NOAF required an electrocardiographically documented episode lasting at least 30 s within 30 days. Clinical surveillance included inpatient telemetry and ECGs, scheduled follow-up and institutional readmissions; individual follow-up completeness was not quantified. We compared categorical characteristics and performed a sensitivity analysis restricted to recorded severe or critical aortic stenosis.
Results: NOAF was documented in 44/218 patients (20.2%; 95% CI, 15.4–26.0%). In the restricted subset, 35/164 had documented NOAF (21.3%; 95% CI, 15.8–28.2%). Chronic obstructive pulmonary disease was more frequent among patients with NOAF (61.4% versus 31.0%; unadjusted OR, 3.53; 95% CI, 1.78–7.01). Pacemaker implantation and low-molecular-weight heparin use were also more frequent in that group, describing perioperative co-occurrence.
Conclusion: Approximately one-fifth of patients had NOAF documented in the available records. Restriction to recorded severe or critical stenosis produced a similar frequency. The estimate describes clinical documentation within a 30-day window and requires interpretation in light of incomplete ascertainment and indication verification.
Related
- Incidence and timing of new-onset atrial fibrillation after transcatheter aortic valve implantation: 14-day electrocardiographic monitoring
- Leadless Pacemaker Implantation in Fabry Disease With Permanent Atrial Fibrillation and Bradycardia: Diagnostic and Implantation Guidance by Preprocedural Cardiac Magnetic Resonance Imaging.
- High Rates of Atrial Fibrillation among Inpatients with Heart Failure or Ischemic Stroke in Southwestern Uganda
- Prognostic Implications of Clinically Attributed Left Atrial Enlargement Subtypes in Patients Undergoing Transcatheter Aortic Valve Implantation.
- Device-detected new-onset atrial fibrillation after dual-chamber pacemaker implantation in patients with sick sinus syndrome under managed ventricular pacing: a risk nomogram from the 3-month landmark
BibTeX
@article{montenegropalacios2026onset,
title = {{New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023}},
author = {John Fernando Montenegro-Palacios and Diana Marcela Bonilla and Antonio Enrique Dager and Jhon Quintana and Carlos Andrés Cardona and Nelson Murillo and Yamil Liscano and Jhony Alejandro Díaz Vallejo and Jamil Cedillo-Balcázar and Mario Valladares Garrido},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = nov,
doi = {10.3389/fcvm.2026.1947079},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1947079/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023
AU - John Fernando Montenegro-Palacios
AU - Diana Marcela Bonilla
AU - Antonio Enrique Dager
AU - Jhon Quintana
AU - Carlos Andrés Cardona
AU - Nelson Murillo
AU - Yamil Liscano
AU - Jhony Alejandro Díaz Vallejo
AU - Jamil Cedillo-Balcázar
AU - Mario Valladares Garrido
PY - 2026
DA - 2026/11/16
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1947079
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1947079/full
AB - Background: New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI). Methods: This retrospective cohort included 218 patients without documented pre-existing atrial fibrillation who underwent TAVI in Cali, Colombia, between 2009 and 2023. NOAF required an electrocardiographically documented episode lasting at least 30 s within 30 days. Clinical surveillance included inpatient telemetry and ECGs, scheduled follow-up and institutional readmissions; individual follow-up completeness was not quantified. We compared categorical characteristics and performed a sensitivity analysis restricted to recorded severe or critical aortic stenosis. Results: NOAF was documented in 44/218 patients (20.2%; 95% CI, 15.4–26.0%). In the restricted subset, 35/164 had documented NOAF (21.3%; 95% CI, 15.8–28.2%). Chronic obstructive pulmonary disease was more frequent among patients with NOAF (61.4% versus 31.0%; unadjusted OR, 3.53; 95% CI, 1.78–7.01). Pacemaker implantation and low-molecular-weight heparin use were also more frequent in that group, describing perioperative co-occurrence. Conclusion: Approximately one-fifth of patients had NOAF documented in the available records. Restriction to recorded severe or critical stenosis produced a similar frequency. The estimate describes clinical documentation within a 30-day window and requires interpretation in light of incomplete ascertainment and indication verification.
SN - 2297-055X
ER -